Bevacizumab
Repackaged Avastin® for intravitreal injection in ophthalmic applications.
Avastin® is a registered trademark of Genentech, Inc. Medivant Healthcare repackages commercially available Avastin® under aseptic conditions.
Product Overview
Bevacizumab (Repackaged Avastin®) is a recombinant humanized monoclonal antibody repackaged into single-use pre-filled syringes for intravitreal injection. This provides convenient, ready-to-use dosing for ophthalmic practices.
| Specification | Details |
|---|---|
| Product Name | Bevacizumab (Repackaged Avastin®) |
| Concentration | 25 mg/mL |
| Fill Volume | 0.07 mL (1.75 mg dose) |
| Container | Pre-Filled Syringe (PFS) |
| Beyond Use Dating | 12 months (frozen) |
| Storage | Frozen, -20°C |
Off-Label Use Notice
Intravitreal bevacizumab is an off-label use of Avastin®. While widely used for retinal conditions, it is not FDA-approved for ophthalmic indications. Prescribers should discuss risks and benefits with patients.
Clinical Applications
- • Age-related macular degeneration (AMD)
- • Diabetic macular edema (DME)
- • Retinal vein occlusion (RVO)
- • Choroidal neovascularization
- • Proliferative diabetic retinopathy
- • Neovascular glaucoma
Pre-Filled Syringe Benefits
- • Ready-to-inject format
- • Consistent dose accuracy
- • Sterile single-use packaging
- • Extended frozen stability
- • Reduced preparation time
Request Product Information
Contact our team for specifications, pricing, and availability.